NCCN updates guidelines for high-grade prostate cancer

NCCN publishes patient resource on genetic testing to guide patient decisionmaking

The National Comprehensive Cancer Network published its first patient resource aimed at informing people about the latest recommendations around hereditary and familial cancer risk. The document provides guidance on testing for inherited genetic mutations that can raise the risk of cancer.

NCCN guidelines updated to include ctDNA-MRD testing recommendation for B-cell lymphoma

The National Comprehensive Cancer Network included circulating tumor DNA testing in their Clinical Practice Guidelines in Oncology for diffuse large B-cell lymphoma. This marks the first-ever inclusion of ctDNA-MRD testing in these guidelines, representing a significant advancement in lymphoma patient care.

January 17, 2025

Vol.51 No.02

Clinical Roundup

A low omega-6, omega-3 rich diet + fish oil may slow prostate cancer growth, UCLA phase III trial finds

A new phase III trial led by UCLA Health Jonsson Comprehensive Cancer Center investigators found that a diet low in omega-6 and high in omega-3 fatty acids, combined with fish oil supplements, significantly reduced the growth rate of prostate cancer cells in men with early-stage disease.

January 10, 2025

Vol.51 No.01

Clinical Roundup

UCLA: Advanced imaging uncovers hidden metastases in high-risk prostate cancer cases

A new study led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center has found that many cases of high-risk nonmetastatic hormone-sensitive prostate cancer may be more advanced than previously thought.

January 10, 2025

Vol.51 No.01

Clinical Roundup

Roswell Park team discovers treatment target for neuroendocrine prostate cancer

A team of researchers at Roswell Park Comprehensive Cancer Center led by Dhyan Chandra has discovered a new therapeutic target for neuroendocrine prostate cancer, a rare and hard-to-treat form of prostate cancer.

January 10, 2025

Vol.51 No.01

Clinical Roundup

HIFU demonstrates positive outcomes in management of prostate cancer, study shows

EDAP TMS SA, the global leader in robotic energy-based therapies, announced the publication of the full results from the HIFI study in European Urology, which has the highest impact factor amongst scientific journals focused in urology. The study evaluated high-intensity focused ultrasound versus radical prostatectomy as a first line treatment of localized prostate cancer.

December 13, 2024

Vol.50 No.46

NCCN updates guidelines for high-grade prostate cancer

YOU MAY BE INTERESTED IN

NCCN publishes patient resource on genetic testing to guide patient decisionmaking

NCCN guidelines updated to include ctDNA-MRD testing recommendation for B-cell lymphoma

A low omega-6, omega-3 rich diet + fish oil may slow prostate cancer growth, UCLA phase III trial finds

UCLA: Advanced imaging uncovers hidden metastases in high-risk prostate cancer cases

Roswell Park team discovers treatment target for neuroendocrine prostate cancer

HIFU demonstrates positive outcomes in management of prostate cancer, study shows

Renew today!

Subscriber content

Never miss an issue!

Login